FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine, in particular to new peptides possessing biocidal, in particular antibacterial, antifungal and antiviral properties and to preparations based on them. Proposed biocidal peptide of the general formula Y-Ile-Leu-Pro-X-Lys-X-Pro-X-X-Pro-X-Arg-Arg-NH2, where X = 4-nitrophenylalanine; 4-chlorophenylalanine; 4-methoxyphenylalanine; D-phenylalanine; 4-aminophenylalanine; 4-aminobenzoylphenylalanine; homophenylalanine; 4-tert-butylphenylalanine; 2-methylphenylalanine; 4-fluorophenylalanine; pentafluorophenylalanine or 2-trifluoromethylphenyl-alanine; Y = H, palmitoyl or aminodecanoyl and the preparation in the form of a gel, having biocidal properties, containing as active principle a peptide in the concentration of 0.001–0.1 wt. %. Inventive peptides exhibit biocidal properties against bacteria, including spore, mold fungi, as well as viruses.
EFFECT: peptide-based gels can be used to treat bacterial, viral, and concomitant infectious diseases.
5 cl, 16 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
AGENT POSSESSING BIOCIDAL ACTION | 2017 |
|
RU2673807C2 |
CYCLIC PROTEIN CONTAINING NO CYSTEINE RESIDUES | 2008 |
|
RU2486196C2 |
HYBRID GENE CONSISTING OF THE RBD RECEPTOR OF THE SURFACE PROTEIN S OF SARS-CoV-2 CORONAVIRUS, S14P5 AND S21P2 EPITOPES, Fc FRAGMENT, FOR OBTAINING A RECOMBINANT ANTIGEN AND ITS USE AS PART OF A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION | 2022 |
|
RU2795160C1 |
HUMANIZED MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO RBD S OF THE PROTEIN OF THE SARS-COV-2 VIRUS, AGENT AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS-COV-2 VIRUS | 2021 |
|
RU2765731C1 |
MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
NEW ANTIBODIES AND NUCLEOTIDE SEQUENCES AND THEIR USE | 2019 |
|
RU2802450C2 |
RECOMBINANT STRAIN OF INFLUENZA VIRUS A/PR8-NS124-TB10_4-2A-HSPX AND METHOD FOR SPECIFIC PREVENTION OF PULMONARY TUBERCULOSIS USING MUCOSAL VACCINE BASED THEREON | 2019 |
|
RU2726106C1 |
PEPTIDE SHOWING BIOCIDE ACTIVITY | 2000 |
|
RU2183643C1 |
IMMUNE-INDUCING AGENT | 2017 |
|
RU2777992C2 |
PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING EYE DISEASES, CONTAINING, AS ACTIVE INGREDIENT, FUSION PROTEIN IN WHICH TISSUE-PENETRATING PEPTIDE AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PREPARATION ARE FUSED | 2016 |
|
RU2712623C2 |
Authors
Dates
2019-02-05—Published
2017-02-06—Filed